Search

Reglagene is pleased to announce that we have been selected as one of the three finalists for Tech Parks Arizona Start Up of the Year! We look forward to the virtual Copper Cactus Awards Ceremony on October 17th.


Breakthrough results in quadruplex science! A research group at the University of Cambridge found quadruplex-stranded DNA in healthy human cells for the first time, as displayed in their publication in Nature. University of Cambridge researchers directly observed DNA quadruplex structures as controllers of gene expression in human cells. First author Marco Di Antonio states that “this forces us to rethink the biology of DNA.”


This finding confirms the revolutionary discoveries made by Reglagene’s CSO Laurence Hurley. Reglagene was founded on the thought of targeting quadruplex structures in cancer genes. By doing this, we can target specific genes and regulate their protein production. Today, Reglagene applies Quadruplex Master Switch Technology (QMST) to create and develop Epigenetic Medicines that save patient lives.

Read more: https://www.newscientist.com/article/2249390-quadruple-stranded-dna-seen-in-healthy-human-cells-for-the-first-time/#ixzz6SrxqJxrn


In April, Reglagene participated in their most successful partnering event to date. Reglagene's CEO Richard Austin had 25 investor partnering meetings in a two day period! Part of this success came from updated pitch decks, executive summaries, and a new tagline, while other successes came from how Reglagene engages with investors throughout the entire process.


Karen Deyo, the Senior Investor Research Analyst at LSN interviewed Richard about his experience and how he pulled off such an incredible two day event.


Click the link below to read the full the interview.


https://blog.lifesciencenation.com/2020/05/07/reglagene-nails-resi-partnering-with-25-investor-meetings/